Department overview
The department uses an MDT model that brings together cellular immunotherapy, targeted therapy, precision radiotherapy, chemotherapy and interventional treatment, complemented by TCM and natural-therapy support. Its published profile also describes access to novel anticancer medicines, clinical research and palliative support for advanced cancer.
Main clinical scope
These areas provide a concise overview. Individual suitability requires clinical assessment.
- Malignant lymphoma
- Lung and breast cancers
- Gastrointestinal cancers
- Gynaecological and genitourinary cancers
- Head and neck cancers
- Rehabilitation and palliative support
Clinical programmes
Principal disease areas, subspecialties and continuous-care services described in the department profile.
Malignant lymphoma
Stratified review for different pathological types and recurrent or refractory disease, with integrated immunotherapy assessed by the clinical team.
Lung cancer
Management informed by biopsy, pathology and genomic testing, including complex drug resistance, recurrence and metastatic disease.
Breast cancer
Molecular-subtype-based treatment with particular attention to high recurrence risk and brain metastasis.
Gastrointestinal tumours
Perioperative and palliative pathways with concurrent management of ascites, obstruction and bleeding.
Gynaecological tumours
Multimodal perioperative care and standardised full-course intervention.
Genitourinary tumours
Stratified management across recurrent, metastatic and castration-resistant disease.
Head and neck tumours
Targeted and immune therapies assessed with attention to both lesion control and organ-function preservation.
TCM and natural-therapy support
Acupuncture, moxibustion, herbal medicine, hyperthermia, nutrition, psychological and mind-body support may contribute to symptom and recovery management.
Featured services and technology
CAR-T and NK-cell therapy
The department profile includes CAR-T and NK-cell therapy and related clinical research; indication, availability and regulatory conditions require case-specific confirmation.
M6 CyberKnife and stereotactic radiotherapy
Image guidance and real-time tracking support highly focused irradiation for selected early-stage or oligometastatic lesions.
Minimally invasive diagnosis and local therapy
CT- or ultrasound-guided biopsy, radiofrequency or microwave ablation, and vascular interventional treatment are described.
Deep hyperthermia and cavity perfusion
Deep-tumour hyperthermia and heated thoracic or abdominal perfusion are described within multimodal management for selected circumstances.
How the department is organised
Oncology, imaging, pathology, radiotherapy, intervention and supportive teams can assess a case together.
Screening, treatment, postoperative conditioning and long-term follow-up are connected within one pathway.
Cell-based therapies, clinical studies and other specialised options require case-specific review of indication, availability and regulatory conditions.
This page introduces service directions and does not provide a diagnosis, treatment recommendation or outcome guarantee. Acceptance, clinical indication, technology availability, risk, fees and specialist schedules are confirmed by Clifford Hospital for each case.